Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Huajie Jin, Senior Health Economist, King's College LondonAbstract: A patient-level WDM was developed using discrete-event simulation (DES) model. The WDM reflects disease and treatment pathways for people at high risk of psychoses or with a diagnosis of schizophrenia, and was used to evaluate options for service change at different points across the whole care pathway. The analyses were conducted from the perspective of the NHS and Personal Social Services (PSS) over a lifetime horizon. The schizophrenia WDM was used to address five decision topics identified from the national institute for health and care excellence (NICE) schizophrenia guidelines, covering cognitive behaviour therapy (CBT), family intervention, antipsychotics and crisis resolution and home treatment team (CRHT). Two alternative decision rules were used: (1) a simple threshold-based decision rule; (2) disease-level constrained maximisation assuming a fixed budget constraint.

The WDM was capable of evaluating the cost and effectiveness outcomes for all 19 interventions covered by the five decision topics and allows investment and disinvestment decisions to be made at the same time. Changes to existing system configurations altered the conclusion of the most cost-effective interventions for two topics; while use of different decision rules altered the conclusion for one topic. The WDM can capture the interactions between interventions and allow use of alternative decision rules, both of which were shown to have an impact on the cost-effectiveness conclusions.

Biography: Huajie Jin (Lily) joined King’s College London in 2013 as a senior health economist. Her research focuses on economic modelling and trial-based economic evaluation for mental health diseases and cancer. Lily gained a BSc in Medicine in the People’s Republic of China in 2008 and completed her MSc in International Health Policy (health Economics stream) at the London School of Economics and Political Science in 2009. Following the completion of her MSc, she worked on the NICE (National Institute for Health and Care Excellence) clinical guidelines for three years: first year as a systematic reviewer, second and third year as a health economist. At the moment, Lily is doing a part-time PhD with KCL. Her PhD aims to build a patient-level whole disease model (WDM) which covers the entire care pathway for schizophrenia. This WDM can be used to compare the cost-effectiveness of all key interventions (CBT, family intervention, antipsychotics, crisis resolution and home treatment team) for schizophrenia patients. 

Forthcoming External Talks

The Health Economic and Policy Seminar Series

Wednesday, 03 April 2024 to Saturday, 31 May 2025